Diet, nutritional status, and certain dietary supplements are postulated to influence the development and progression of prostate cancer. Angiogenesis and inflammation are central to tumor growth and progression, but the effect of diet on these processes remains uncertain. We explored changes in 50 plasma cytokines and angiogenic factors (CAF) in 145 men with prostate cancer enrolled in a preoperative, randomized controlled phase II trial with four arms: control (usual diet), low-fat (LF) diet, flaxseed-supplemented (FS) diet, and FS+LS diet. The mean duration of dietary intervention was 30 to 31 days. Among the individual arms, the largest number of significant changes (baseline vs. preoperative follow-up) was observed in the LF arm, with 19 CAFs decreasing and one increasing (P < 0.05). Compared with the control arm, 6 CAFs—including proangiogenic factors (stromal-cell derived-1α) and myeloid factors (granulocyte-colony-stimulating factor, macrophage colony-stimulating factor)—all decreased in the LF arm compared with controls; three and four CAFs changed in the FS and FS+LF arms, respectively. Weight loss occurred in the LF arms and significantly correlated with VEGF decreases (P < 0.001). The CAFs that changed in the LF arm are all known to be regulated by NF-κB, and a pathway analysis identified NF-κB as the most likely regulatory network associated with these changes in the LF arm but not in the FS-containing arms. These results suggest that a LF diet without flaxseed may reduce levels of specific inflammatory CAFs and suggests that the NF-κB pathway may be a mediator of these changes. Cancer Prev Res; 4(10); 1590–8. ©2011 AACR.
Aside from nonmelanoma skin cancer, prostate cancer is the most common cancer among men in the United States, with an estimated 217,730 new diagnoses in 2010 (1). Gathering evidence suggests that a plant-based, low-fat (LF) diet inhibits prostate cancer development and progression (2–4). Furthermore, obesity has been associated with an increased risk of high-grade, but a decreased risk of low-grade, prostate cancer (5).
A limited number of randomized clinical trials have suggested that LF diets and certain dietary supplements may inhibit prostate cancer development and progression and improve clinical outcomes in prostate cancer patients (6). In a small proof-of-concept randomized clinical trial, dietary fat restriction altered serum fatty acid levels and decreased growth of LNCaP cancer cells treated with the collected sera of patients (7). Specific mechanisms linking a high-fat diet with prostate cancer remain unclear; although previous studies have implicated NF-κB, a transcription factor whose activation has been linked to cancer. In a mouse model of prostate cancer, NF-κB was found to be upregulated in a moderate fat/carbohydrate group, and these mice had shorter survival than mice on a high-fat/carbohydrate-free diet or a LF/high-carbohydrate diet (8).
NF-κB seems to be a key regulator of energy balance and inflammation. Obesity and a diet high in fat have been found to induce an inflammatory response mediated by NF-κB (9, 10). Studies in mouse models of obesity show that a high-fat diet can increase NF-κB activation, which in turn leads to a sustained elevation of inhibitory κB (IκB) kinase ϵ (IKKϵ) levels in liver, adipocytes, and adipose tissue macrophages, resulting in chronic low-grade inflammation and also increased levels of circulating proinflammatory cytokines (11, 12). Consistent with these observations, clinical studies have shown that a high-fat meal can lead to increased NF-κB activation from peripheral blood mononuclear cells and that obese individuals express higher levels of NF-κB (vs. leaner individuals; ref. 13). This is accompanied by higher circulating levels of proinflammatory cytokines and angiogenic factors (CAF) such as TNF-α, interleukin 6 (IL-6), macrophage migration inhibitory factor, and matrix metallopeptidase 9 (12, 13). Most recently, increased activation of NF-κB, along with elevated levels of proinflammatory TNF-α, IL-1β, and COX-2 was detected in the mammary gland and visceral fat in both dietary (high fat diet) and genetic obesity mouse models (14). This study suggests that NF-κB is an important mediator of an inflammatory response following increased saturated fatty acid exposure and may contribute to breast cancer development through an inflammatory-mediated induction of aromatase, which is involved in the biosynthesis of estrogens (14, 15). Taken together, these studies provide evidence of a linkage between obesity and an NF-κB–dependent inflammatory response that may ultimately contribute to the tumorigenic process.
Cytokines associated with obesity or secreted by adipose tissue may play a significant role in a sustained systemic state of inflammation which has been shown to increase the risk for the development of cancer (16–20). In addition, TNF-α, which has been shown to contribute to insulin resistance in obesity and obesity-linked type-2 diabetes, induces several NF-κB–activating transcription factors and genes, as well as other genes involved in cell growth, proliferation, and inflammation (21, 22). Taken together, these findings potentially link obesity to upregulation of NF-κB–regulated proinflammatory CAFs that lead to a variety of adverse medical conditions, including increased risk for prostate cancer.
Other dietary changes including a diet high in lignans, such as traditional plant-based diets, have also been postulated to lower the incidence of prostate cancer (23). The most abundant source of dietary lignans is flaxseed. Once consumed, the plant lignans are converted by the intestinal microflora to the 2 major mammalian estrogenic enterolignans: enterodiol and enterolactone (24). Both of these enterolignans are able to reduce cell viability of prostate cancer cells (25–27). Furthermore, flaxseed is a rich source of omega-3 fatty acids, which are also thought to inhibit neoplasia and to do so potentially through several mechanisms including modulation of the synthesis of prostaglandins and thromboxanes.
Previously, we conducted a randomized controlled phase II trial (RCT) of flaxseed supplementation (30 g of ground flaxseed per day) and/or a LF diet (fat intake <20% of total energy intake) in prostate cancer patients (28). Whereas nonsignificant trends toward lower Ki-67 proliferation rates were found with the LF diet, significantly lower proliferation rates were observed in both flaxseed arms. However, this effect was not accompanied by reductions in serum prostate-specific antigen (PSA), testosterone, sex hormone-binding globulin, insulin-like growth factor (IGF)-1, or IGF-binding protein-3, which were hypothesized to be the responsible mechanisms of action.
Given the emerging associations between dietary factors, inflammation, and prostate cancer progression, and the lack of understanding about the potential mechanisms by which these factors may be linked, in this study we have explored changes in circulating inflammatory CAFs occurring in men with prostate cancer following LF or flaxseed-supplemented (FS) diets.
Materials and Methods
Patients and study design
The methods and outcomes of this phase II RCT have been reported previously (28, 29). Briefly, 161 men with clinically confirmed prostate cancer who were scheduled for radical prostatectomy were randomized to one of the following conditions: usual diet (control), FS diet (30 g/d), LF diet (fat intake <20% of total energy), or FS (30 g/d), LF diet (fat intake <20% total energy, FS+LF, Fig. 1). All participants adhered to the dietary regimen for at least 21 days and on average for 30 days, prior to their scheduled surgery. The primary endpoint was tumor proliferation as determined by Ki-67 staining, and major secondary endpoints were the rate of apoptosis and expressions of a number of biomarkers associated with both prostate cancer growth and dietary status. The study protocol was approved by the Institutional Review Board of Duke University Medical Center and sites associated with the University of Michigan Community Clinical Oncology Program. Written informed consent was obtained from all study participants. As noted in the main outcomes paper, proliferation rate significantly decreased in the flaxseed arms; however, significant weight loss as well as a decrease in serum cholesterol was noted in men assigned to the LF diet condition.
The nuclear localization of p65 and the expression of VEGF and COX-2 were evaluated using an immunohistochemical method described previously (30). In brief, tumor samples were fixed with paraformaldehyde and embedded in paraffin. After being washed in PBS, the slides were blocked with protein block solution (DakoCytomation) for 20 minutes and incubated overnight with rabbit polyclonal anti-human p65 (Abcam) and mouse monoclonal anti-human VEGF (Santa Cruz Biotechnology) and COX-2 (Cayman Chemical Company; 1:400, 1:100, and 1:200, respectively). Slides were washed and incubated with biotinylated link universal antiserum, followed by horseradish peroxidase–streptavidin conjugate (LSAB + kit). The slides were rinsed, and color was developed using 3, 3-diaminobenzidine hydrochloride as a chromogen. Finally, sections were rinsed in distilled water, counterstained with Mayer's hematoxylin, and mounted with DPX mounting medium for evaluation. Expression levels of p65, VEGF, and COX-2 were determined by counting at least 500 tumor cells in 10 representative hpf and the percentage of p65 (nuclear), and the expression of VEGF and COX-2 were calculated in all cases. The percent positive cells were then represented graphically for each marker.
Plasma sample collection and analysis
Blood samples were collected in Vacutainer tubes (Becton Dickinson) containing EDTA anticoagulant and centrifuged at 1,500 × g for 10 minutes at 4°C within 30 minutes of collection. The plasma was placed in prelabelled cryovials and stored at −80°C until analysis. A total of 50 CAFs were measured using multiplexed bead suspension arrays (MBA) as previously described (31, 32). Samples were thawed overnight at 4°C prior to analysis, centrifuged at 1,500 × g to remove debris and then aliquoted and analyzed in duplicate by MBA. Baseline and follow-up samples from a given patient were assessed simultaneously on the same plate to minimize the potential impact of interassay variability.
All statistical analyses were done using R (http://www.r-project.org) and SAS, Statistical Analysis System version 9.1 (SAS Institute). Prepost samples existed on 145 study participants consisting of 37 controls, 40 FS, 33 LF, and 35 FS+LF. Participants who were taking steroids during the study period (n = 5) were removed from the analysis to reduce potential confounding effects that such agents, or the conditions for which such agents are prescribed, might have on inflammatory markers. The percent change from baseline was defined as the percentile of the median at follow-up divided by the median at baseline; significance was defined by P < 0.05 by paired t tests for each arm. For the primary analysis of CAF changes within arms, an adjustment for multiple comparisons (Bonferroni correction) was done (Table 1). Two sample t tests were used to identify significant changes in CAFs between the control arm and each of the modified diet conditions using change scores (the difference between baseline and follow-up). To produce heat maps, the CAF change data was normalized by computing the z-score (subtracting by the average and dividing by the standard error). Common observations across 6 markers were used to generate the heat map. Pathway analysis was conducted on the markers observed to change significantly in the modified diet arms; because this was an exploratory analysis, an alpha level of <0.10 was used. The dataset containing the gene identifiers along with the corresponding mean differences was loaded into the Ingenuity Pathway Analysis program (Ingenuity Systems). Given that significant weight loss was observed in the LF arms, and body weight status has been associated with prostate cancer progression, linear models were used to explore significant associations between changes in marker scores and changes in body mass index (BMI). The correlation between changes in CAFs and BMI were calculated using Pearson correlation estimates and were graphed using scatter plots.
|Control .||LF .||FS .||FS + LF .|
|Control .||LF .||FS .||FS + LF .|
All are P < 0.05 except as denoted by
a, P < 0.001.
Abbreviations: ICAM-1, intercellular adhesion molecule-1; IL-1RA, interleukin-1 receptor antagonist; IL-2RA, interleukin-2 receptor alpha; LIF, leukemia inhibitory factor; MCP, macrophage chemoattractant protein; PDGF, platelet-derived growth factor; SCF, stem cell factor, SCGF-β, stem cell growth factor-beta; VCAM-1 vascular cell adhesion molecule-1.
Of the 161 patients enrolled in this trial, a majority were over the age of 65 (74%) and were overweight (46%) or obese (35%). Most of the patients had earlier stage disease with biopsy Gleason sums of 6 or less (66%). The average duration on the diet was 30 to 31 days. Baseline and follow-up (presurgery) plasma samples were available on 145 patients. An overview of the clinical trial design and the collection times for plasma and prostatic tissue is shown in Figure 1.
CAF changes within individual arms
We initially assessed changes in CAFs (preoperative follow-up vs. baseline) in each arm individually and then compared CAF changes in the 3 intervention arms with those in the control arm. For the individual arms, CAFs that showed statistically significant change (P < 0.05) or a borderline trend toward change (P < 0.1) between baseline and follow-up in each arm are shown in the Supplementary Table S1. The largest number of significant changes occurred in the LF arm (N = 20), with all but 1 (PDGF-BB) decreasing, whereas 11, 9, and 10 CAFs changed significantly within the control, FS, and LF+FS arms, respectively. These changes remained significant when adjusted for multiple comparisons (Bonferroni correction), shown in Table 1. Many of these decreases were modest in magnitude, with ≥10% change noted for 9 CAFs in the LF arm versus 2 CAFs in the control arm and 4 in other 2 arms. CAFs decreasing in the LF arm included proangiogenic factors such as hepatocyte growth factor (HGF) and stromal-cell derived-1α (SDF-1α) and inflammatory cytokines, including several involved in myeloid recruitment and proliferation such as macrophage colony-stimulating factor (M-CSF), growth-regulated oncogene α (GRO-α)), and eotaxin. There was also an observed decrease in the proinflammatory cytokine IL-10.
Comparison of changes in CAFs between the arms
We then compared CAF changes for each analyte in the intervention arms with the changes for the same analyte in the control arm (i.e., change for analyte in control minus the change for the analyte in the intervention arm). As compared with the control, men in the LF arm experienced significantly greater decreases in 6 CAFs (Fig. 2). Decreases in the mean difference between baseline and follow-up compared with the control were observed in the LF arm for the proangiogenic factors SDF-1α; the hematopoietic growth factor G-CSF (granulocyte colony-stimulating factor) as well as cytokines with roles in cell differentiation and recruitment of myeloid cells including eotaxin, M-CSF, respectively. Decreases were also detected in the immunosuppressor TNF-β, which has been proposed to provide tumors with escape from immune surveillance (33).
By contrast, in the FS arm, only 3 CAFs changed significantly compared with the control arm, an increase in IL-8 and a decrease in eotaxin and IP-10 were observed (Fig. 2).
When the combination arm, FS+LF, was compared with the control arm, the decrease in eotaxin continued to be observed, along with MIP1-α. However, 2 cytokines showed a significant increase, the hematopoietic growth factor SCF and the neurotrophic growth factor β-NGF (Fig. 2).
Coordinate changes in CAFs in patients following a LF diet and their association with the NF-κB pathway
To gain a better understanding of the relationship between changes in the different CAFs, we carried out hierarchical clustering analysis of the 6 CAFs previously identified to have significant changes between the control and the LF arm (Fig. 3A). Each row represents the mean difference of each CAF from the control, with each column representing a patient in either the control group (blue color) or the LF group (red color). Red denotes decreases in CAF concentration at follow-up compared with control and green indicates increased concentration at follow-up. Changes in many of these cytokines seemed to be coordinated with each other within a given patient, with a majority of these factors decreasing in the LF arm compared with the control arm. This suggests that the coordinate changes in these cytokines may potentially be regulated by common mechanism(s). To identify potential regulators of these 6 CAFs, we conducted an Ingenuity Pathway Analysis which revealed a network of significant relationships between these factors (Fig. 3B). This analysis identified the NF-κB complex as a central node. NF-κB was not identified as a central node for the FS-containing arms (data not shown).
Correlation between weight loss and decreases in serum cholesterol and CAF changes
Given that the larger decreases in CAFs may have been mediated by weight loss, and also may be associated with serum lipids, we explored these associations (28) and detected a significantly positive association between the change in BMI and the change in VEGF (P = 0.0009) as seen in Figure 4 and significant negative associations (P < 0.05), with 6 other factors including the TNF-related apoptosis-inducing ligand (TRAIL) and IL-2RA (Supplementary Table S2). These 3 CAFs were among those for which the CAF changes were significantly associated with changes in cholesterol levels (Supplementary Table S3), suggesting a potential impact of the LF diet. We also assessed the association between CAF and PSA and observed that changes in several members of the IL family (IL-1b, -4, -7, and -9), as well as IFN-γ, were positively correlated with PSA changes (P < 0.05 for all; Supplementary Table S4).
Tumor expression of angiogenic and inflammatory markers
We analyzed protein levels of VEGF and markers for potential angiogenic factors and cytokine regulatory pathways including NF-κB, COX-2, and the hypoxia-inducible marker CA-9 in a limited subset of postsurgical prostate cancer specimens (N = 40) by immunohistochemistry. VEGF was not reduced in the FS arm, but the other markers showed a nonsignificant trend (Fig. 5). Because sufficient prestudy biopsy specimens were not available, it was not possible to investigate tumor changes for individual patients during the study.
This secondary analysis of 50 CAFs was undertaken to explore potential mechanisms by which the LF diet or flaxseed supplementation may influence prostate cancer development and progression. The results suggest that although flaxseed supplementation influenced a few CAFs, the LF diet seemed to exert a greater impact and decreased levels of a number of circulating proinflammatory CAFs. In the LF arm, significant changes were observed for 6 CAFs, the majority of which were proinflammatory factors, involved in the myeloid (e.g., G-CSF, M-CSF, and eotaxin) or proangiogenic factors (e.g., SDF-1α). In comparison, in the combination arm (FS+LF), we only detected significant decreases in eotaxin and MIP-1α and increases in SCF and β-NGF. It is not known whether these changes are primarily because of the LF diet itself, weight loss, or some other factor (s). The fact that we observed such a strong correlation between changes in BMI and changes in VEGF suggests that weight loss or LF diet may impact inflammatory and angiogenic responses.
Moreover, the decreases in the 6 CAFs in the LF arm seemed to occur in a coordinated manner, suggesting that the expression of some or all of these CAFs may be governed by a common regulatory mechanism. Pathway analysis identified the NF-κB pathway as a signaling node that interacted with a majority of the CAFs that decreased in the LF arm. Each of these factors has previously been reported to be regulated by NF-κB (10, 34). In addition, the immunohistochemical analysis of a subset of prostatectomy tumor specimens revealed a trend toward lower levels of NF-κB and COX-2 expressions. For VEGF, lower expression was observed for the LF arm as compared with controls. Meanwhile, a slight increase in VEGF expression was observed for the FS and FS+LF arms as compared with the control. These findings are consistent with the decreased levels of proangiogenic factors detected in the plasma of these patients. Caution, however, is necessary in interpreting these findings because this analysis was highly exploratory and only was done on a limited number of specimens. Thus, further study is needed.
NF-κB, a central mediator of the inflammatory response, angiogenesis, and invasion is constitutively activated in many cancers (33, 35–37). Several recent studies have indicated that the NF-κB pathway plays a critical role in regulating energy balance and provides a link between diet and inflammation. A high-fat diet has been shown to increase NF-κB activation, and furthermore, knockout of the NF-κB target, IKKϵ, prevented diet-induced obesity and chronic inflammation in mouse models (11, 14, 38). Observations from another study found that human subjects experience increases in NF-κB activation in peripheral blood mononuclear cells within hours of eating a high-fat meal (39). In light of these previous studies findings and the findings of this study that the majority of CAFs that decreased in patients in the LF arm were known to be NF-κB regulated, our data suggest that a LF diet induced downregulation of the NF-κB pathway may have contributed to changes in circulating proinflammatory and angiogenic CAFs. However, not all known NF-κB–regulated factors (e.g., TNF-α and IL-6) decreased between baseline and preoperative follow-up (just prior to prostatectomy) in the LF arm, indicating that other pathways known to impact inflammatory and angiogenic pathways, such as the COX-2 and hypoxia-inducible factor-1α pathways, may have contributed to the changes we observed (40).
The results of this study raise several questions when compared with the previously published analysis of prostate cancer specimens, in which tumors from men on the flaxseed arm had a lower rate of proliferation based on Ki-67 staining than those in the LF or control groups (28). The first issue is whether Ki-67 or the CAFs in this study are appropriate surrogate markers for clinical outcome in prostate cancer. It is worth noting that in the prior study, only postoperative Ki-67, and not changes in Ki-67, was assessed; therefore, the impact of the dietary intervention on a particular patient could not be evaluated. Tumor proliferation, inflammation, and angiogenesis have all been linked to cancer progression in a variety of different settings, but given the design and size of the current study, it is not possible to determine which, if any, of the markers is associated with prostate cancer progression or clinical outcome in the preoperative setting for prostate cancer. It is plausible that separate mechanisms govern the putative effects of flaxseed on tumor cell proliferation and of a LF diet on inflammatory and angiogenic CAFs. Further studies will be needed to identify these mechanisms and determine their impact on prostate cancer.
Another issue that remains unresolved is why the many changes in cytokines observed in the LF arm are not mirrored in the FS+LF arm. It is worth noting that although both the LF and FS+LF groups experienced a significant decrease in BMI (28), the LF group had a slightly higher loss which may have impacted the cytokine changes. Furthermore, it is conceivable that the addition of flaxseed may have altered the pattern of CAF changes, or that at least some of the changes in the LF arm were due to chance alone. The observations that 19 of 20 of the CAFs in the LF arm changed in the same direction (decreased), however, and that many of these changes occurred in a coordinated manner as seen in Figure 3, argue against these changes being solely because of chance.
To our knowledge, this study is the first to report changes in plasma levels of CAFs resulting from dietary changes in prostate cancer patients. Prior studies have suggested that dietary factors influence prostate cancer development and progression. In addition, given that previous studies have shown higher rates of prostate cancer with high-fat diets, as well as associations between obesity and more aggressive disease, the mechanisms identified in this exploratory analysis involving the LF diet may merit further investigation (41, 42). Indeed, mounting evidence suggests that obesity is associated with chronic inflammation, which is characterized by an influx of circulating inflammation-related markers (43). Adipose tissue itself is highly vascularized and is capable of promoting angiogenesis through the production and release of angiogenic factors, such as VEGF (44–46). Preclinical studies have shown that mice on a LF diet experience a reduction in prostate cancer growth and have lower serum insulin and IGF-1 levels, compared with mice fed on a Western diet (47). Adding serum from men on a LF, high-fiber diet and an exercise intervention to androgen-independent LNCaP cells also has been found to decrease growth, increase apoptosis, and reduce NF-κB activation (45, 48). Taken together, these studies suggest that diet-induced changes in inflammatory and/or angiogenic factors may influence the growth of prostate cancer.
In this study, we also observed decreases in the proinflammatory cytokine TNF-β (lymphotoxin) in the LF arm. TNF-β can bind to the TGF-βR1, the same receptor as TNF-α and TGF-R2, and is thus an important activator of NF-κB (49, 50). In a murine obesity model, elevated levels of TNF-α contributed to the development of hepatocellular carcinoma, suggesting obesity-mediated increased TNF-1α contributes to the tumorigenic process (17). TNF-α was also found to be elevated in parallel with activated NF-κB in the mammary gland in a diet-induced murine obesity model (14). This is in line with our study, in which patients following a LF diet in the LF arm exhibited decreases in TNF-β that could potentially mediate decreased NF-κB activity and contribute to the changes in CAFs.
In addition, significant decreases in eotaxin emerged in all 3 treatment arms. Eotaxin has proangiogenic effects through chemotaxis of microvascular endothelial cells and plays a role as a chemoattractant for eosinophils, basophils, and Th2 lymphocytes (51). Eotaxin expression is induced by proinflammatory cytokines such as TNF-α, IFN-α, and glucocorticoids (20). A previous study showed that there exists a link between obesity and eotaxin serum levels in obese (high-fat diet induced) mouse models as well as in obese human serum and omental fat (52). Similar to the results in this study, serum eotaxin levels were reduced in patients who experienced diet-induced weight loss. An NF-κB binding site is present within the eotaxin promoter (along with STAT-6, IFN-α response, and glucocorticoid response element; ref. 51), suggesting that decreased NF-κB activity following a LF diet is a plausible mechanism for eotaxin changes observed in this study.
This study had several potential limitations. Given the modest sample size, our findings might not be transferable to other studies. There was no adjustment for multiple comparisons given the exploratory nature of this analysis. A number of the CAFs, we assessed, can be affected by factors other than diet, such as stress, and may be greatly changed in a subset of individuals but would not reflect the effect of diet modulation on the cohort as a whole. The presence of a control diet arm, however, should reduce some of these confounding factors. Furthermore, the biologic changes mediated by these changes in CAFs may not have been accurately shown because of the short mean time period (30–31 days) of adhering to the diet on this study. Finally, it is not possible to determine whether changes in CAF were the result of changes in the tumor, the host, or a combination of the two and whether greater changes may have occurred in the tumor microenvironment than was observed in mixed venous blood. The findings from this study would therefore need to be validated in a larger study, and a longer on-study duration time, and would ideally include paired tumor biopsies that would enable one to distinguish tumor versus host effects.
In summary, this study was the first to investigate the effects of LF and FS diets on circulating CAFs in prostate cancer patients. Although relatively few changes in CAFs were observed with flaxseed supplementation, it does not negate the possibility that other mechanisms may be at play. In contrast, the LF diet seemed to spur a coordinated reduction among a set of inflammatory cytokines, particularly among those involved in myeloid cell recruitment and proliferation, and several angiogenic factors. The changes with a LF diet occurred in factors regulated by NF-κB. Combined with emerging evidence that the NF-κB pathway plays a critical role in coupling energy balance with inflammatory and angiogenesis, our findings suggest that NF-κB is a potential mediator of the changes in circulating CAFs associated with a LF diet. Although these changes might be expected to reduce inflammation and tumor angiogenesis, the magnitude of these changes (detectable in mixed venous blood) were often modest, and their impact on prostate cancer or other cancer types remains unknown and warrants further investigation. Therefore, this study is hypothesis generating, and additional studies are needed to investigate the potential links between diet, the NF-κB pathway, inflammation, angiogenesis, and cancer biology.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
This study was supported by NIH grants CA85740, CA07464830, M01-RR-30, and CA16672, the Cancer Center Support Grant (CCSG) of The University of Texas MD Anderson Cancer Center. K-A. Do was partially supported by the SPORE in Prostate Cancer (CA90270) at MD Anderson Cancer Center. J.V. Heymach is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04) and the American Society for Clinical Oncology Career Development Award.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.